These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 37442207)

  • 1. Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review.
    Dong J; Yuan L; Hu C; Cheng X; Qin JJ
    Pharmacol Ther; 2023 Sep; 249():108488. PubMed ID: 37442207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp).
    Zhang H; Xu H; Ashby CR; Assaraf YG; Chen ZS; Liu HM
    Med Res Rev; 2021 Jan; 41(1):525-555. PubMed ID: 33047304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
    To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
    J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function.
    Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC
    Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
    Pérez-Tomás R
    Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update.
    Dong J; Qin Z; Zhang WD; Cheng G; Yehuda AG; Ashby CR; Chen ZS; Cheng XD; Qin JJ
    Drug Resist Updat; 2020 Mar; 49():100681. PubMed ID: 32014648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2.
    Silbermann K; Shah CP; Sahu NU; Juvale K; Stefan SM; Kharkar PS; Wiese M
    Eur J Med Chem; 2019 Feb; 164():193-213. PubMed ID: 30594677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function.
    Dai CL; Liang YJ; Chen LM; Zhang X; Deng WJ; Su XD; Shi Z; Wu CP; Ashby CR; Akiyama S; Ambudkar SV; Chen ZS; Fu LW
    Biochem Pharmacol; 2009 Aug; 78(4):355-64. PubMed ID: 19410561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
    Teodori E; Dei S; Martelli C; Scapecchi S
    Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.
    Ranjbar S; Khonkarn R; Moreno A; Baubichon-Cortay H; Miri R; Khoshneviszadeh M; Saso L; Edraki N; Falson P; Firuzi O
    Toxicol Appl Pharmacol; 2019 Jan; 362():136-149. PubMed ID: 30391378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
    Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G
    Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.
    Choi YH; Yu AM
    Curr Pharm Des; 2014; 20(5):793-807. PubMed ID: 23688078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.
    Wang YJ; Kathawala RJ; Zhang YK; Patel A; Kumar P; Shukla S; Fung KL; Ambudkar SV; Talele TT; Chen ZS
    Biochem Pharmacol; 2014 Aug; 90(4):367-78. PubMed ID: 24937702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).
    Heffeter P; Jakupec MA; Körner W; Chiba P; Pirker C; Dornetshuber R; Elbling L; Sutterlüty H; Micksche M; Keppler BK; Berger W
    Biochem Pharmacol; 2007 Jun; 73(12):1873-86. PubMed ID: 17445775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2.
    Wu CP; Hsieh YJ; Tseng HY; Huang YH; Li YQ; Hung TH; Wang SP; Wu YS
    Biomed Pharmacother; 2022 Oct; 154():113663. PubMed ID: 36081287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.